Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 5Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Leukemia 43Recurrence 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Non-Hodgkin 21Hematologic Neoplasms 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Leukemia, Myeloid 11Neoplasm, Residual 10Myeloproliferative Disorders 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Multiple Myeloma 9Lymphoma, Mantle-Cell 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Chromosome 17 deletion 6Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia, B-Cell 5Burkitt Lymphoma 5Primary Myelofibrosis 4GATA2 Deficiency 4Blast Crisis 4

Interventions

fludarabine phosphate 6Cyclophosphamide 6fludarabine 4Whole-Body Irradiation 4Mycophenolic Acid 4tagraxofusp 3Thiotepa 3Methotrexate 3Cyclosporine 3venetoclax 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Dexamethasone 2Cytarabine 2Cyclosporins 2Calcium Dobesilate 2Azacitidine 2merphos 1lorvotuzumab mertansine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Vincristine 1Sirolimus 1Salvia hispanica seed extract 1Rituximab 1Ranitidine 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Blastic Plasmacytoid Dendritic Cell Neoplasm × venetoclax × Other hematologic neoplasm × Clear all
NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Terminated
235 enrolled
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03113643 2025-11-04

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Dana-Farber Cancer Institute

Phase 1 Recruiting
72 enrolled
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡